Back to all assets

Veeva Systems VEEV

equity

Price History

$19.21$123.71$228.21$332.71
2013-10 · DCA start$38.91

Time underwater

How far below its previous all-time high the price sat, each month. 0% means a new high.

-53.1%-35.4%-17.7%0.0%
2013-102026-08 · -27.4%

Worst drawdown: −53%, peaking Jul 2021 and bottoming Apr 2026 — still unrecovered after 61 months.

DCA Backtest

Invested
$15,500
Value today
$52,281
Return
+237.3%
Months invested
155

Scenarios

Inflation — the same contributions merely keeping pace with CPI would be $19,256 today, so the real (inflation-adjusted) return is +171.5%.

Lump sum instead — $15,500 all at once in Oct 2013: $96,207 (+520.7%) — lump sum came out ahead.

Worst timing — same monthly amount started at the all-time high (Jul 2021): $7,145 on $6,200 invested (+15.2%).

⚠ Price returns only — dividends are not included. This understates the true return of dividend-paying shares, and any comparison against crypto (which pays no dividends) is biased against equities by roughly the dividend yield, compounded.

If this saved you a spreadsheet — buy me a coffee.

Every start month at once

Each cell is the return-to-date of £/$/€100-a-month DCA started that month. Click a cell to load it in the backtest above. The ringed cell is the all-time-high start — the worst timing scenario.

JFMAMJJASOND
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Legend:−50%−20%0%+50%+200%+1000%worst timing (ATH)Selected 2013-10: +237.3%

About Veeva Systems

Veeva Systems Inc., headquartered in Pleasanton, California, provides cloud computing software, data, and consulting services for the life sciences industry. Its products are used to track all aspects of drug development and pharmaceutical manufacturing. (Wikipedia)

It's a listed company categorised under health care and health care technology, with a market cap of about $39.1B.

It rates Medium-Low Risk at 2.0/5, meaning the rated factors are mostly sound, with one or two areas worth watching.

What pushes the score up: market / volatility (3.0/5) and sector / regulatory (3.0/5).

Scoring well: earnings quality at 1.0/5.

Not yet researched: leverage / financial, concentration, governance. These are excluded from the score rather than guessed, so the real risk may be higher than what’s shown.

Ratings summarise sourced facts against fixed rules — not investment advice, and no substitute for your own diligence.

Risk Profile

Medium-Low Risk(2.0/5)60% rated

How these ratings work

Market / Volatility3.0/5 · weight 20%
  • Annualised volatility (3yr)3/532.7
  • Max drawdown from ATH3/553.1
  • Beta vs S&P 5003/50.94
Liquidity1.0/5 · weight 15%
  • Avg daily $ volume1/5550.0m
  • Float % of shares outstandingnot yet researched
Leverage / Financialunrated · weight 20%
  • Debt / equitynot yet researched
  • Interest coverage (EBIT / interest)not yet researched
Earnings Quality1.0/5 · weight 15%
  • 3yr EPS volatility1/55.8
Concentrationunrated · weight 10%
  • Largest customer, % of revenuenot yet researched
  • Geographic revenue concentrationnot yet researched
Governanceunrated · weight 10%
  • Board independence %not yet researched
  • Share structurenot yet researched
  • Litigation / audit historynot yet researched
Sector / Regulatory3.0/5 · weight 10%
  • Sector regulatory exposure3/5elevated

Linked Assets

Same sector, or return-correlated — worth knowing what else might move if this one does.